You are here
China cancer patients turn to unapproved drugs on grey market
WHEN her father's lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly US$3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
Ms Yin, like many families in
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org